United States, Feb. 26 -- The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program. The application was filed on January 13, 2026. In the clinical trial data submitted to the agency, a remarkable 76% of previously untreated patients had a substantial decrease in tumor size, representing a significant improvement from the current standard of care whereby 30-45% of patients are typically expected to demonstrate this response. Lung cancer kills more Americans annually than any other type of cancer, with an estimated 226,650 new diagnoses and 124,730 deaths in 2025, according to the National Cancer Institute....